BR9707638A - Particula contendo lipìdeos, escolhidas dentre iscoms e matriz de iscoms, e, preparacao de vacina para profilaxia e/ou imunoterapia. - Google Patents

Particula contendo lipìdeos, escolhidas dentre iscoms e matriz de iscoms, e, preparacao de vacina para profilaxia e/ou imunoterapia.

Info

Publication number
BR9707638A
BR9707638A BR9707638-4A BR9707638A BR9707638A BR 9707638 A BR9707638 A BR 9707638A BR 9707638 A BR9707638 A BR 9707638A BR 9707638 A BR9707638 A BR 9707638A
Authority
BR
Brazil
Prior art keywords
iscoms
chosen
containing lipids
immunotherapy
prophylaxis
Prior art date
Application number
BR9707638-4A
Other languages
English (en)
Inventor
Bror Morein
Bengtsson Karin Loevgren
Jill Ekstroem
Original Assignee
Bror Morein
Bengtsson Karin Loevgren
Jill Ekstroem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bror Morein, Bengtsson Karin Loevgren, Jill Ekstroem filed Critical Bror Morein
Publication of BR9707638A publication Critical patent/BR9707638A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"PARTìCULA CONTENDO LIPìDEOS, ESCOLHIDAS DENTRE ISCOMS E MATRIZ DE ISCOMS, E, PREPARAçãO DE VACINA PARA PROFILAXIA E/OU IMUNOTERAPIA". As partículas contendo lipídeos como iscoms, matriz de iscoms, ou vesículas, como micelas ou lipossomas que compreendem uma ou mais moléculas de receptor hidrófobo para marcação e substâncias antigênicas, cujas moléculas de receptor foram integradas na partículas e são escolhidas dentre receptores contendo lipídeos ou receptores que são hidrófobos, cujas moléculas de receptor se ligam às substâncias antigênicas.
BR9707638-4A 1996-02-21 1997-02-20 Particula contendo lipìdeos, escolhidas dentre iscoms e matriz de iscoms, e, preparacao de vacina para profilaxia e/ou imunoterapia. BR9707638A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9600648A SE9600648D0 (sv) 1996-02-21 1996-02-21 Receptorbimdande enhet
PCT/SE1997/000287 WO1997030726A1 (en) 1996-02-21 1997-02-20 Iscom or iscom-matrix comprising hydrophobic receptor molecules for antigenic substances

Publications (1)

Publication Number Publication Date
BR9707638A true BR9707638A (pt) 2000-01-04

Family

ID=20401482

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9707638-4A BR9707638A (pt) 1996-02-21 1997-02-20 Particula contendo lipìdeos, escolhidas dentre iscoms e matriz de iscoms, e, preparacao de vacina para profilaxia e/ou imunoterapia.

Country Status (12)

Country Link
US (1) US6027732A (pt)
EP (1) EP0944397B1 (pt)
AT (1) ATE258066T1 (pt)
AU (1) AU718443B2 (pt)
BR (1) BR9707638A (pt)
CA (1) CA2247103C (pt)
DE (1) DE69727314T2 (pt)
DK (1) DK0944397T3 (pt)
ES (1) ES2214608T3 (pt)
NZ (1) NZ331418A (pt)
SE (1) SE9600648D0 (pt)
WO (1) WO1997030726A1 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
US6693086B1 (en) * 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
WO2000048630A1 (en) 1999-02-17 2000-08-24 Csl Limited Immunogenic complexes and methods relating thereto
EP1239876B1 (en) * 1999-11-19 2008-07-30 Csl Limited Hcv vaccine compositions
SE0003538D0 (sv) * 2000-09-29 2000-09-29 Isconova Ab New immunogenic complex
US7713942B2 (en) * 2001-04-04 2010-05-11 Nordic Vaccine Technology A/S Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides
US20030138434A1 (en) * 2001-08-13 2003-07-24 Campbell Robert L. Agents for enhancing the immune response
WO2003059380A2 (de) * 2002-01-15 2003-07-24 Bio Life Science Forschungs Und Entwicklungsges M.B.H. Orale vakzinierung
AU2004226605A1 (en) * 2003-04-02 2004-10-14 Coley Pharmaceutical Group, Ltd. Immunostimulatory nucleic acid oil-in-water formulations for topical application
US20050013812A1 (en) * 2003-07-14 2005-01-20 Dow Steven W. Vaccines using pattern recognition receptor-ligand:lipid complexes
TWI235440B (en) * 2004-03-31 2005-07-01 Advanced Semiconductor Eng Method for making leadless semiconductor package
KR100958505B1 (ko) * 2004-07-18 2010-05-17 씨에스엘 리미티드 면역자극 복합체 및 향상된 인터페론-감마 반응을 유도하기위한 올리고뉴클레오티드 제제
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
PT2468300T (pt) 2006-09-26 2018-01-30 Infectious Disease Res Inst Composição para vacina contendo adjuvante sintético
ES2325243B1 (es) * 2008-02-27 2011-05-04 Universidad De Granada Antigeno recombinante.
CN102481312B (zh) 2009-06-05 2015-07-15 传染性疾病研究院 合成的吡喃葡萄糖脂佐剂
WO2012141984A1 (en) 2011-04-08 2012-10-18 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
PL2811981T3 (pl) 2012-02-07 2019-09-30 Infectious Disease Research Institute Ulepszone formulacje adiuwantowe zawierające agonistę TLR4 oraz sposoby ich zastosowania
KR102136433B1 (ko) 2012-05-16 2020-07-22 이뮨 디자인 코포레이션 Hsv-2 백신
EP2986303B1 (en) 2013-04-18 2020-02-26 Immune Design Corp. Gla monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
IL310015B2 (en) 2013-12-31 2026-02-01 Access To Advanced Health Inst Single vial formulation
EP3976092A1 (en) 2019-05-25 2022-04-06 Infectious Disease Research Institute Composition and method for spray drying an adjuvant vaccine emulsion
EP4058581A1 (en) 2019-11-15 2022-09-21 Infectious Disease Research Institute Rig-i agonist and adjuvant formulation for tumor treatment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2403081A1 (fr) * 1977-09-19 1979-04-13 Merieux Inst Nouveau materiau particulaire, sa preparation et son application, notamment comme medicament
US5178860A (en) * 1989-09-01 1993-01-12 Coopers Animal Health Limited Adjuvant complexes and vaccine made therefrom
NL9002314A (nl) * 1990-10-23 1992-05-18 Nederlanden Staat Immunogene complexen, in het bijzonder iscoms.

Also Published As

Publication number Publication date
EP0944397A1 (en) 1999-09-29
NZ331418A (en) 2000-03-27
AU718443B2 (en) 2000-04-13
ES2214608T3 (es) 2004-09-16
ATE258066T1 (de) 2004-02-15
EP0944397B1 (en) 2004-01-21
WO1997030726A1 (en) 1997-08-28
AU2238397A (en) 1997-09-10
DE69727314D1 (de) 2004-02-26
SE9600648D0 (sv) 1996-02-21
CA2247103A1 (en) 1997-08-28
DK0944397T3 (da) 2004-06-01
DE69727314T2 (de) 2004-11-18
CA2247103C (en) 2009-01-20
US6027732A (en) 2000-02-22

Similar Documents

Publication Publication Date Title
BR9707638A (pt) Particula contendo lipìdeos, escolhidas dentre iscoms e matriz de iscoms, e, preparacao de vacina para profilaxia e/ou imunoterapia.
AR002705A1 (es) Un nuevo compuesto de indolina, un proceso para su preparacion y composiciones farmaceuticas que lo contienen.
AR010752A1 (es) COMPUESTOS QUE SE ENLAZAN A Y ACTIVAN UN RECEPTOR DE LA TROMBOPOYETINA; COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN, SU USO PARA LA PREPARACION DE MEDICAMENTOS, Y PROCESO PARA PREPARAR DICHA COMPOSICIoN.
ES2109685T3 (es) Composiciones para vacunas que contienen monofosforil-lipido a 3-o-desacilado.
AU7980794A (en) Methods and compositions for microencapsulation of antigens for use as vaccines
EA200100713A1 (ru) Препаративная форма галантамина с регулируемым выделением
ES2118630T3 (es) Composicion que contiene un aerogel, procedimiento para su preparacion, asi como su empleo.
MX9703793A (es) Un material mixto que comprende un aerogel, un procedimiento para su preparacion y su uso.
AR001686A1 (es) Una composición vacuna un proceso para prepararla y su uso para la fabricación de una vacuna
ES2075746T3 (es) Particulas de oxido de titanio y metodo para producirlas.
AU4622693A (en) Potentiation of immunogenic response
ATE476410T1 (de) Alicyclische ester mit moschusgeruch
ES2104133T3 (es) Composiciones cosmeticas o farmaceuticas que contienen glicerofosfolipidos desacilados para uso topico.
NZ295238A (en) Immunogenic compositions characterised by the carrier being a hydrophobic solvent in the absence of a hydrophilic phase
ES2148458T3 (es) Derivados de fenil-4-tiazoles sustituidos, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
CO5150178A1 (es) Bromohidrato de eletriptan monohidrato y procedimiento para su preparacion
SE8206250D0 (sv) Reglering av tarmmikroflora
BR9710849A (pt) Vacina contendo uma peróxi-redoxina e/ou uma beta-tubulina.
NL940015I1 (nl) 4-Hydroxy- respectievelijk 4-c2-c12-acyloxy-4-androsteen-3,17-dionen in gemicroniseerde vorm
AU6814387A (en) Phenylacetonitriles which are substituted by basic groups, their preparation and drugs containing these substances
BR9106272A (pt) Composicoes farmaceuticas contendo ipriflavona,processo para sua preparacao e uso terapeutico relativo
NO307403B1 (no) Fremgangsmåte for tørr fremstilling av partikler, tørrfremstilte partikler oppnådd på denne måte, samt farmasøytiske blandinger som inneholder slike partikler
MX9307203A (es) COMPUESTOS ESTEROIDALES DE ACIL-3-CARBOXI-3,5-DIENO-17Ó Y 17ß -SUBSTITUIDOS.
MX9207264A (es) Compuestos de sulfonimidamida, procedimiento para su preparacion y formulaciones farmaceuticas que los contienen
ES2032914T3 (es) Procedimiento para preparar composiciones con diclorotrifluoetano.

Legal Events

Date Code Title Description
FF Decision: intention to grant
HJEG Technical examination (opinion): technical examination (opinion) related to article 229 of industrial property law
HIFF Patent grant cancelled
FF Decision: intention to grant
HHFI Decision: rectification
HHFI Decision: rectification
FG9A Patent or certificate of addition granted
B24H Lapse because of non-payment of annual fees (definitively: art 78 iv lpi)
B24F Patent annual fee: publication cancelled

Free format text: ANULADA A PUBLICACAO CODIGO 24.8 NA RPI NO 2258 DE 15/04/2014 POR TER SIDO INDEVIDA.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE AS 15A, 16A, 17A, 18A, 19A E 20A ANUIDADES.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2607 DE 22-12-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.